TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 615730633
Drug: Parenteral diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral diazepam bolus
Study: 615730633
Drug: Parenteral diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral diazepam continuous infusion
Study: 615730633
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (bolus and infusion)
Study: 34377934
Drug: Adjuvant clodronate
Normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant clodronate (1600 mg daily for 3 years)
Study: 32286643
Drug: Vaccine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine (20 µg, n = 201)
Study: 33045330
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal bupivacaine (LB) 133 mg with 7.5 mL of 0.5% and 7.5 mL of 0.25% plain bupivacaine
Study: 33045330
Drug: Plain bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain bupivacaine 25 mL of 0.5%
Study: 33215755
Drug: Conventionally loaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventionally loaded implants
Study: 33270911
Drug: chronoIFLO5 (irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: chronoIFLO5 (irinotecan 180 mg/sqm, oxaliplatin 80 mg/sqm, fluorouracil 2800 mg/sqm, leucovorin 1200 mg/sqm) administered every 3 weeks for 5 days
Study: 32205276
Drug: 3-D printed
Normalized name: trans-resveratrol 3-β-D-glucoside
DrugBank: Polydatin (DB11263)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-D printed porous titanium implants
Study: 34388297
Drug: Tofogliflozin 20
Normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Tofogliflozin 20 mg/d
Study: 35100917
Drug: HIPEC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIPEC with cisplatin (60 mg/m2 administered on days 1 and 3, 30 mg/m2 each time) plus oral S‐1 (40–60 mg, twice daily for 14 days)
Study: 35100917
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treated with cisplatin (60 mg/m2 intravenously) plus oral S‐1 (40–60 mg, twice daily for 14 days)
Study: 35346549
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg daily for 14 days
Study: 32553717
Drug: TDF 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF 300 mg/emtricitabine (FTC) 200 mg, 7 doses/week (perfect adherence)
Study: 32553717
Drug: TDF 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF 300 mg/emtricitabine (FTC) 200 mg, 4 doses/week (moderate adherence)
Study: 32553717
Drug: TDF 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF 300 mg/emtricitabine (FTC) 200 mg, 2 doses/week (low adherence)
Study: 35112974
Drug: sorafenib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorafenib (400 mg/day)
Study: 37206222
Drug: KCZ‐ILs (KCZ,
Approvals — FDA: no, EMA: no, PMDA: no
Description: KCZ‐ILs (KCZ, 4.72 mg/g)
Study: 37206222
Drug: Daktarin® (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daktarin® (control group; KCZ, 20 mg/g)
Study: 34289330
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus vouchers for attendance (VOU)
Study: 34289330
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus text reminders (REM)
Study: 34289330
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus vouchers and text reminders (VOU + REM)
Study: 34289330
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment alone (STD)
Study: 32847776
Drug: Duloxetine 30
Normalized name: duloxetine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 30 mg (D30, N = 22)
Study: 32847776
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg (D60, N = 22)
Study: 32847776
Drug: Duloxetine 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 90 mg (D90, N = 22)
Study: 33428233
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) at 40 ppm
Study: 33796915
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and atezolizumab
Study: 36141627
Drug: 2 servings/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 servings/day of nutritionally complete ONS powder (Fresubin® Powder), 600 kcal, 22.4 g protein for 12 weeks
Study: 34193499
Drug: Preference-based smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preference-based smoking cessation intervention (STOP) using various nicotine substitutes (patches, inhalers, gum, tablets, etc.) and/or electronic cigarettes delivered free of charge.
Study: 34021843
Drug: Concurrent chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiation with cisplatin (CCRT)
Study: 32191600
Drug: Leucine supplementation
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucine supplementation (0.06 g/kg/meal; n = 10)
Study: 32191600
Drug: Alanine control
Normalized name: Alanine
DrugBank: Alanine (DB00160)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alanine control (0.06 g/kg/meal; n = 10)
Study: 36158131
Drug: TPVB (thoracic
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPVB (thoracic paravertebral block) with 15 mL of 0.375% ropivacaine hydrochloride
Study: 32324592
Drug: immunotherapy (IT)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: immunotherapy (IT) + anti-VEGFR (aVEGFR) + platinum-based therapy (Plat)
Study: 32324592
Drug: immunotherapy (IT)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: immunotherapy (IT) + aVEGFR + Plat
Study: 32798360
Drug: Other oral
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other oral hypoglycaemic agents, insulin or statins
Study: 34698901
Drug: Lorlatinib 100
Normalized name: lorlatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorlatinib 100 mg single oral dose
Study: 34698901
Drug: Lorlatinib 50
Normalized name: LORLATINIB
DrugBank: Lorlatinib (DB12130)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lorlatinib 50 mg intravenous (IV) dose
Study: 34698901
Drug: Both oral
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both oral and IV lorlatinib
Study: 32635768
Drug: Diuretic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic treatment in black patients
Study: 32635768
Drug: Diuretic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic treatment in nonblack patients
Study: 32833109
Drug: N-acetylcysteine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine administration
Study: 35608802
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy (ST)
Study: 35499850
Drug: 0.7 mg/kg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7 mg/kg/d fenfluramine
Study: 35499850
Drug: 0.2 mg/kg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg/d fenfluramine
Study: 33369488
Drug: 7 days
Normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days of preoperative antibiotics
Study: 33369488
Drug: 2 days
Normalized name: Chapstick 12 Days of Christmas KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 days of preoperative antibiotics
Study: 36223712
Drug: Personalized Mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized Mg treatment (mean dose 205.58 mg/day, range 77.25 to 389.55 mg/day)
Study: 36223712
Drug: Personalized Mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized Mg treatment
Study: 34941423
Drug: molnupiravir (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: molnupiravir (800 mg)
Study: 34941423
Drug: molnupiravir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: molnupiravir (400 or 800 mg)
Study: 35050343
Drug: AI system
Normalized name: AI-128
DrugBank: AI-128 (DB05841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AI system for subtask 2 (treatment planning)
Study: 37186577
Drug: Azithromycin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (20 mg/kg)
Study: 35308069
Drug: Chronic L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic L-arginine supplementation (5 g, twice a day for 13 days)
Study: 35308069
Drug: Acute L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute L-arginine supplementation (5 g)
Study: 35308069
Drug: Chronic placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic placebo supplementation (5.5 g dextrin, twice a day for 13 days)
Study: 35308069
Drug: Acute placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute placebo supplementation (5.5 g dextrin)
Study: 34864156
Drug: Empirical dietary/lifestyle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical dietary/lifestyle interventions and laxative therapy
Study: 34864156
Drug: General treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: General treatment options
Study: 34076977
Drug: Cisplatin treatment
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin treatment (0 μM, 2 μM, 4 μM, 8 μM, 16 μM)
Study: 33137100
Drug: Community-wide mass
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-wide mass drug administration (MDA) with albendazole targeting eligible individuals of all ages (20 clusters)
Study: 616777178
Drug: Intra-articular lumbar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular lumbar facet joint corticosteroid injection
Study: 34780683
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg once daily
Study: 32515067
Drug: Compassion-focused therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compassion-focused therapy (CFT) group intervention, 12 sessions, 2 hours each
Study: 33378717
Drug: Bimanual or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimanual or unimanual intensive therapy
Study: 34874418
Drug: YEARS rule
Approvals — FDA: no, EMA: no, PMDA: no
Description: YEARS rule combined with age-adjusted D-dimer threshold (D-dimer <1000 ng/mL or <500 ng/mL for age <50 years or age in years × 10 for patients ≥50 years)
Study: 32384509
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatment (co‐qingdai capsule, compound glycyrrhizin tablet, AA Skincare jojoba Oil)
Study: 39536238
Drug: Tirzepatide 15
Normalized name: tirzepatide 15 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirzepatide 15 mg
Study: 39536238
Drug: Tirzepatide 5
Normalized name: tirzepatide 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirzepatide 5 mg
Study: 35634931
Drug: IAT (conventional-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: IAT (conventional-dose cytarabine, idarubicin, and thioguanine)
Study: 35634931
Drug: IdAraC-Ida (intermediate-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: IdAraC-Ida (intermediate-dose cytarabine and idarubicin)
Study: 35624408
Drug: Eliapixant 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eliapixant 750 mg
Study: 33986030
Drug: Eliapixant ≥50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eliapixant ≥50 mg
Study: 33986030
Drug: Eliapixant (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eliapixant (all doses)
Study: 32394478
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy (ESWT) - 2000 shocks, frequency of 3 Hz, maximum total energy flow density 0.25 mJ/mm2, once a week for 4 weeks
Study: 36383907
Drug: Antibody-drug conjugates
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibody-drug conjugates (ADCs)
Study: 34839332
Drug: Off drug
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Off drug (3-month follow-up)
Study: 34631030
Drug: Methylnaltrexone (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylnaltrexone (12 mg once daily or 12 mg once every other day; oral methylnaltrexone 150, 300, or 450 mg daily)
Study: 35323856
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with TPC (paclitaxel, cisplatin, capecitabine)
Study: 35323856
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with PF (cisplatin, fluorouracil)
Study: 35323856
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with TPC
Study: 32847735
Drug: Never tried
Approvals — FDA: no, EMA: no, PMDA: no
Description: Never tried to lose at least 10 lbs, ate 0−2 servings of fruits and vegetables daily, or engaged in 0−29 min of physical activity weekly
Study: 32527192
Drug: Intensified loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified loading strategy (ILS) with prasugrel 60 mg
Study: 32527192
Drug: Standard loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard loading strategy with clopidogrel 600 mg
Study: 37541951
Drug: Ketamine (subanaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (subanaesthetic doses)
Study: 33906086
Drug: Abemaciclib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abemaciclib (150 mg twice daily) + fulvestrant/NSAI
Study: 33559090
Drug: AEA group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: AEA group (antofloxacin 200 mg once daily, esomeprazole 20 mg + amoxicillin 1000 mg twice daily for 14 days)
Study: 34628742
Drug: Acupuncture and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture and medication group 1 (2 Hz continuous wave)
Study: 34628742
Drug: Acupuncture and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture and medication group 2 (50 Hz continuous wave)
Study: 34628742
Drug: Acupuncture and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture and medication group 3 (2 Hz/50 Hz disperse-dense wave)
Study: 34628742
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (conventional medication)
Study: 35123290
Drug: Dialectical behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical behavior therapy (DBT)
Study: 34414814
Drug: Joint mobilization
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Joint mobilization and therapeutic exercises (physical therapy group)
Study: 33992570
Drug: CRT-P (Cardiac
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRT-P (Cardiac Resynchronization Therapy without Defibrillator)
Study: 32896992
Drug: Single-dose regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose regimen of methotrexate (MTX)
Study: 32896992
Drug: Triple-dose regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-dose regimen of methotrexate (MTX)
Study: 33574371
Drug: Pomegranate juice
Normalized name: pomegranate juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate juice (8 oz daily)
Study: 35144303
Drug: Femoral triangle
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femoral triangle block (FTB) and interspace between the popliteal artery and the capsule of the posterior knee (IPACK)
Study: 35144303
Drug: Intra-articular cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular cocktail analgesic mixture local injection
Study: 32990311
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy visits (number and timing)
Study: 32675019
Drug: 52 mL/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 52 mL/day EVOO
Study: 32675019
Drug: DieTBra +
Approvals — FDA: no, EMA: no, PMDA: no
Description: DieTBra + 52 mL/day EVOO
Study: 35780807
Drug: Odevixibat 40
Normalized name: ODEVIXIBAT 400MCG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odevixibat 40 μg/kg per day
Study: 38670135
Drug: Odevixibat 120
Normalized name: ODEVIXIBAT 1200MCG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odevixibat 120 μg/kg per day
Study: 35780807
Drug: Combined odevixibat
Normalized name: Odevixibat
DrugBank: Odevixibat (DB16261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Combined odevixibat group (40 μg/kg and 120 μg/kg)
Study: 32894637
Drug: Early combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early combination therapy (metformin plus vildagliptin)
Study: 35852694
Drug: Test cream
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test cream (steroid + synthetic pseudo‐ceramide), applied twice daily for 2 weeks
Study: 35852694
Drug: Control cream
Normalized name: BENZOYL PEROXIDE 3 mg in 60 mL TOPICAL LIQUID [Acnecare Dermacontrol Cream]
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control cream (steroid without pseudo‐ceramide), applied twice daily for 2 weeks
Study: 32467099
Drug: First-line platinum-based
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-line platinum-based chemotherapy
Study: 36169608
Drug: Isotope phosphorus-32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotope phosphorus-32 dressing combined with diprospan and mucopolysaccharide polysulphate cream
Study: 36169608
Drug: Diprospan combined
Normalized name: Irospan Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diprospan combined with mucopolysaccharide polysulphate cream
Study: 36169608
Drug: Isotopic phosphorus-32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotopic phosphorus-32 dressing combined with mucopolysaccharide polysulphate cream
Study: 34521166
Drug: Bioabsorbable steroid-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioabsorbable steroid-eluting sinus stent in one frontal sinus ostium (FSO)
Study: 35305325
Drug: E-cigarette product
Normalized name: vitamin E Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: E-cigarette product placement in music videos (treatment group)
Study: 34350385
Drug: Volasertib (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volasertib (350 mg intravenous on days 1 and 15 in 4‐wk cycles) combined with low‐dose cytarabine (LDAC; 20 mg subcutaneous, twice daily, days 1‐10)
Study: 34350385
Drug: Volasertib (V)
Normalized name: Penicillin V
DrugBank: Volasertib (DB12062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volasertib (V) plus low‐dose cytarabine (LDAC)
Study: 36243199
Drug: Seasonal influenza
Normalized name: seasonal influenza, intradermal, preservative free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seasonal influenza vaccine
Study: 34166373
Drug: Single ultrasound-guided
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ultrasound-guided hyaluronic acid injection
Study: 35646743
Drug: Fufang Furong
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fufang Furong Effervescent Suppository
Study: 33106174
Drug: non-invasive cervical
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-invasive cervical VNS (nVNS) for 5 days in addition to standard treatment
Study: 33106174
Drug: standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard treatment alone
Study: 37245250
Drug: No β-blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: No β-blocker therapy
Study: 32215899
Drug: Iomeprol 400
Normalized name: Iomeprol 400 MG/1 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iomeprol 400 mg/ml (group A)
Study: 32215899
Drug: Iomeprol 300
Normalized name: Iomeprol 300 MG/1 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iomeprol 300 mg/ml (group B)
Study: 35103366
Drug: Intralesional injection
Normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injection of tuberculin PPD
Study: 35103366
Drug: Cryotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryotherapy plus intralesional injection of tuberculin PPD
Study: 34477473
Drug: Prolonged-release Hydeal-D
Normalized name: loratadine / pseudoephedrine Extended Release Oral Tablet [Alavert D]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release Hydeal-D 0.2% vaginal gel applied every three days for 12 weeks
Study: 34477473
Drug: Prolonged-release Hydeal-D
Normalized name: loratadine / pseudoephedrine Extended Release Oral Tablet [Alavert D]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release Hydeal-D 0.2% vaginal gel
Study: 32729363
Drug: Antiviral drugs
Normalized name: antiviral drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral drugs (specific drugs not mentioned)
Study: 32729363
Drug: Multi-drug combination
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-drug combination therapy
Study: 32802264
Drug: NSDP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSDP plus supragingival irrigation with aerosolized 0.5% hydrogen peroxide (H2O2) solution
Study: 32302347
Drug: Melatonin 20mg
Normalized name: melatonin 20 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin 20mg before and during the first cycle of chemotherapy
Study: 35154575
Drug: Silymarin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin (400 mg/day) along with DAAs (Sofosbuvir 400 mg/day and Ribavirin 800 mg/day) for 8 weeks
Study: 35154575
Drug: DAAs (Sofosbuvir
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAAs (Sofosbuvir 400 mg/day and Ribavirin 800 mg/day)
Study: 32618122
Drug: Gabapentin at
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin at 20 mg/kg per day
Study: 34844816
Drug: Extracorporeal Shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal Shock Wave Therapy (ESWT) with 512 impulses of 0.15mJ/mm2, twice per week for 4 weeks
Study: 34844816
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for burn scars
Study: 32845997
Drug: Intravenous N-Acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous N-Acetylcysteine (NAC)